Uniqure B.V. (QURE) 9.27 $QURE
Nasdaq stocks posting largest percentage increases
AP - 19 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
3 Stocks Rising on Big Volume
at The Street - Mon Apr 28, 7:41AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
uniQure Announces Changes in Management Team
GlobeNewswire - Wed Apr 09, 6:08AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Eric Goossens as its new Chief Operating Officer with a primary responsibility for manufacturing and project management. Mr. Goossens has a 15-year track record of management and leadership in technology-based companies, including the biopharmaceutical industry, with particular experience in the oversight of operations and site management. In addition, uniQure welcomed Deya Corzo, M.D., in the position of Vice President, Medical Affairs for the United States as of April 1, 2014.
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
uniQure Announces Results for Financial Year 2013
GlobeNewswire - Wed Mar 26, 7:12AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced unaudited results for the financial year ended December 31, 2013. As of December 31, 2013, the Company held cash and cash equivalents of EUR23.8 million.
uniQure to Present at Future Leaders in Biotech Conference
GlobeNewswire - Fri Mar 21, 10:35AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present a corporate overview at the 21 Annual Future Leaders in the Biotech Industry Conference March 28, 2014, to be held at the Millennium Broadway Hotel, New York City, NY, USA.
uniQure and Chiesi Announce Six Year Follow-up Data from Glybera(r) Treated Patients
GlobeNewswire - Mon Mar 17, 5:18AM CDT
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"
, a leading international pharmaceutical company, today announced initial analysis of retrospectively collected individual patient data from LPLD patients treated with Glybera. The analysis covers follow-up data for up to six years post treatment for 13 patients, all of whom met indication requirements for the current labeling of Glybera in the EU. This analysis represents an extension of the case note review which formed a part of the data package upon which the European Commission approved Glybera in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. Glybera currently is not approved for use outside of the European Union.
Forbion Announces Closing of Initial Public Offering of Portfolio Company uniQure
Business Wire - Thu Feb 13, 3:30AM CST
Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, is proud to announce that its portfolio company uniQure N.V. (uniQure or the company) has closed its initial public offering of ordinary shares at an initial public offering price of $17.00 per ordinary share. uniQure's ordinary shares are listed on the NASDAQ Global Select Market and began trading under the symbol "QURE" on February 5, 2014. Jefferies LLC and Leerink Partners LLC acted as joint book-running managers and Piper Jaffray & Co. acted as lead manager for the offering.
uniQure Announces Closing of Initial Public Offering
GlobeNewswire - Mon Feb 10, 8:53AM CST
uniQure B.V. ("uniQure", a leader in human gene therapy, today announced the closing of its previously announced initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share. In addition, uniQure granted the underwriters a 30-day option from February 5, 2014 to purchase up to an additional 810,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. uniQure's ordinary shares were approved for listing on the NASDAQ Global Select Market and began trading under the symbol "QURE" on February 5, 2014.
uniQure Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Feb 05, 7:05AM CST
uniQure B.V. ("uniQure", a leader in human gene therapy, today announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share. In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 810,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the initial public offering are expected to be approximately $81.9 million. The offering is expected to close on or about February 10, 2014, subject to customary closing conditions. uniQure's ordinary shares have been approved for listing on the NASDAQ Global Select Market and are expected to begin trading under the symbol "QURE" on February 5, 2014.
Nasdaq stocks posting largest percentage increases
AP - 19 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
3 Stocks Rising on Big Volume
at The Street - Mon Apr 28, 7:41AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
uniQure Announces Changes in Management Team
GlobeNewswire - Wed Apr 09, 6:08AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Eric Goossens as its new Chief Operating Officer with a primary responsibility for manufacturing and project management. Mr. Goossens has a 15-year track record of management and leadership in technology-based companies, including the biopharmaceutical industry, with particular experience in the oversight of operations and site management. In addition, uniQure welcomed Deya Corzo, M.D., in the position of Vice President, Medical Affairs for the United States as of April 1, 2014.
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
uniQure Announces Results for Financial Year 2013
GlobeNewswire - Wed Mar 26, 7:12AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced unaudited results for the financial year ended December 31, 2013. As of December 31, 2013, the Company held cash and cash equivalents of EUR23.8 million.
uniQure to Present at Future Leaders in Biotech Conference
GlobeNewswire - Fri Mar 21, 10:35AM CDT
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its management will present a corporate overview at the 21 Annual Future Leaders in the Biotech Industry Conference March 28, 2014, to be held at the Millennium Broadway Hotel, New York City, NY, USA.
uniQure and Chiesi Announce Six Year Follow-up Data from Glybera(r) Treated Patients
GlobeNewswire - Mon Mar 17, 5:18AM CDT
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"
, a leading international pharmaceutical company, today announced initial analysis of retrospectively collected individual patient data from LPLD patients treated with Glybera. The analysis covers follow-up data for up to six years post treatment for 13 patients, all of whom met indication requirements for the current labeling of Glybera in the EU. This analysis represents an extension of the case note review which formed a part of the data package upon which the European Commission approved Glybera in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. Glybera currently is not approved for use outside of the European Union. Forbion Announces Closing of Initial Public Offering of Portfolio Company uniQure
Business Wire - Thu Feb 13, 3:30AM CST
Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, is proud to announce that its portfolio company uniQure N.V. (uniQure or the company) has closed its initial public offering of ordinary shares at an initial public offering price of $17.00 per ordinary share. uniQure's ordinary shares are listed on the NASDAQ Global Select Market and began trading under the symbol "QURE" on February 5, 2014. Jefferies LLC and Leerink Partners LLC acted as joint book-running managers and Piper Jaffray & Co. acted as lead manager for the offering.
uniQure Announces Closing of Initial Public Offering
GlobeNewswire - Mon Feb 10, 8:53AM CST
uniQure B.V. ("uniQure"
, a leader in human gene therapy, today announced the closing of its previously announced initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share. In addition, uniQure granted the underwriters a 30-day option from February 5, 2014 to purchase up to an additional 810,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. uniQure's ordinary shares were approved for listing on the NASDAQ Global Select Market and began trading under the symbol "QURE" on February 5, 2014. uniQure Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Feb 05, 7:05AM CST
uniQure B.V. ("uniQure"
, a leader in human gene therapy, today announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share. In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 810,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the initial public offering are expected to be approximately $81.9 million. The offering is expected to close on or about February 10, 2014, subject to customary closing conditions. uniQure's ordinary shares have been approved for listing on the NASDAQ Global Select Market and are expected to begin trading under the symbol "QURE" on February 5, 2014. 
